Beyond ADCs: FAP-Targeted Small-Molecule Conjugates for Tumour-Selective Delivery of Immunostimulatory Payloads
12:00 pm - Monday 8th March 2027
- Introducing small-molecule drug conjugates (SMDCs) as an innovative approach for targeted cancer therapy, highlighting their design principles and potential advantages for selective payload delivery
- Exploring novel payloads beyond conventional cytotoxic agents, with a particular focus on small-molecule conjugates designed to promote localized immune activation within the tumour microenvironment
- Sharing preclinical findings demonstrating the anti tumour potential of FAP-targeted small-molecule conjugates, including their ability to induce potent and durable anti-tumour responses